MERVIN C YODER, MD
Medical Practice at Riley Hospital Dr, Indianapolis, IN

6521225, Feb 18, 2003

Sep 2, 1997

08/921497

Arun Srivastava - Indianapolis IN
Selvarangan Ponnazhagan - Cleveland OH
Xu-Shan Wang - Carmel IN
Mervin C. Yoder - Indianapolis IN
Jaime Escobedo - Alamo CA
Varavani Dwarki - Alameda CA

Chiron Corporation - Emeryville CA
Advanced Research and Technology Institute - Bloomington IN

A61K 3500

424 932, 424 931

The present invention is directed to a recombinant adenovirus vector comprising two inverted terminal repeats (ITRs) each of which comprises a D-sequence having (i) from 5 to 15 native nucleotides and (ii) one or more deletions or substitutions therein.

2001005, Dec 13, 2001

Jul 24, 2001

09/912680

Arun Srivastava - Indianapolis IN, US
Selvarangan Ponnazhagan - Cleveland OH, US
Robert Schloemer - Indianapolis IN, US
Xu-Shan Wang - Carmel IN, US
Mervin Yoder - Indianapolis IN, US
Jaime Escobedo - Alamo CA, US
Varavani Dwarki - Alameda CA, US

Chiron Corporation.

A61K048/00, C12N015/861

514/044000, 435/320100

Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.

2003016, Sep 4, 2003

Mar 28, 2002

10/109799

Arun Srivastava - Indianapolis IN, US
Selvarangan Ponnazhagan - Cleveland OH, US
Robert Schloemer - Indianapolis IN, US
Xu-Shan Wang - Carmel IN, US
Mervin Yoder - Indianapolis IN, US
Jaime Escobedo - Alamo CA, US
Varavani Dwarki - Alameda CA, US

Chiron Corporation - Emeryville CA

A61K048/00, C12N015/861

435/456000, 424/093200

Provided are methods for selectively expressing therapeutic molecules, such as secretory proteins, antisense molecules and ribozymes, in the liver. The methods find use in treating hepatic diseases or conditions. The methods also find use in treating any disease or condition in which systemic administration of the therapeutic substance, for example, a secretory protein, is desired. The methods involve administering to a mammalian patient having a need for liver expression of a therapeutic molecule an AAV vector containing a therapeutically effective amount of the therapeutic molecule. Also provided are novel vectors employable in these methods.

2005026, Dec 1, 2005

Feb 9, 2005

11/055182

Mervin Yoder - Indianapolis IN, US
David Ingram - Indianapolis IN, US

C12N005/08

435372000

A hierarchy of endothelial colony forming cells (EPCs) was identified from mammalian cord blood, umbilical vein and aorta. A newly isolated cell named high proliferative potential—endothelial colony forming cell (HPP-ECFC) was isolated and characterized. Single cell assays were developed that test the proliferative and clonogenic potential of endothelial cells derived from cord blood, or from HUVECs and HAECs. EPCs were found to reside in vessel walls. Use of a feeder layer of cells derived from high proliferative potential-endothelial colony forming cells (HPP-ECPCS) from human umbilical cord blood, stimulates growth and survival of repopulating hematopoietic stem and progenitor cells. Stimulation of growth and survival was determined by increased numbers of progenitor cells in in vitro cultures and increased levels of human cell engraftment in the NOD/SCID immunodeficient mouse transplant system.

2008002, Jan 31, 2008

Aug 13, 2007

11/837999

Mervin Yoder - Indianapolis IN, US
David Ingram - Indianapolis IN, US
Daniel Prater - Fishers IN, US

Indiana University Research and Technology Corporation - Indianapolis IN

A61K 35/12, A61P 9/00, C12N 5/02, C12N 5/08

424093700, 435325000, 435402000

Methods and compositions to form fully functional blood vessels in vivo using endothelial colony forming cells (ECFCs) are disclosed. Culturing ECFCs in a support material results in association of ECFCs in vitro and formation of blood vessels in vivo upon implantation. Direct administration of cultured ECFCs form blood vessels in vivo. Formation of blood vessels is useful in treating a variety of medical conditions including ischemia and hypoxia.

2009028, Nov 12, 2009

Dec 10, 2008

12/332084

Seth Kreger - New Richmond IN, US
Mervin C. Yoder - Indianapolis IN, US
Paul Critser - Indianapolis IN, US

A61K 9/00, A61K 35/12, C12N 5/06, C12N 9/48

424484, 424 937, 435395, 435212

Collagen based-matrices and methods of their use are described. More particularly, collagen-based matrices for differentiating stem cells and progenitor cells, and for producing and isolating blood vessels and vascularized graft constructs are described.